Genmab — August 2020
-
Haha sikke et ikke svar fra judith på 2021 read outs
-
Det her bliver vist en tynd omgang
-
Og Jan ham-stringer endda Judith - det er sgu nye tider
-
Men det lyder til at det er lidt af et horse race med Roche på Ecoritamab
-
Det er ret fedt, at høre den competitive edge fra GEN
-
Judith ser TF target som proof of concept for andre programmer
-
Inkluderer 4 yderligere tumor targets
-
Cannot provide commitment
-
Men kommer i future
-
Spændende for TF programmet
-
Dara har 24% patient share - driven by earlier patient uptake
-
1st line 3 fold uptake
-
135k patients treated dara
-
9% 1st line
-
42% 2st line
-
op fra 3% og 34%
-
Der er ikke meget “flavour” på judiths svar
-
Tak troldmand
-
Epco - expedited path?
-
Hun er lidt af en våd klud i sine svar
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind